The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

French drugmaker Sanofi said the U.S. Food and Drug Administration ... The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the ...

Sanofi (SNY)'s share was trading at $51.06 ... by deep public-sector distribution—generated €2.25 billion, and MenQuadfi, a meningitis vaccine, posted 50.5% growth. Despite some expected ...

While it’s largely preventable through vaccines such as Sanofi’s own MenQuadfi, infection of the most severe form, bacterial meningitis, can be fatal within just 24 hours and remains a ...